Low skeletal muscle mass and post-operative complications after surgery for liver malignancies: a meta-analysis

Abstract

Purpose To assess the influence of low skeletal muscle mass (LSMM) on post-operative complications in patients with hepatic malignancies grade (Clavien Dindo ≥ 3) undergoing resection. Methods MEDLINE, Cochrane, and SCOPUS databases were screened for associations between sarcopenia and major post-operative complications (≥ grade 3 according to Clavien-Dindo classification) after resection of different malignant liver tumors. RevMan 5.3 software was used to perform the meta-analysis. The methodological quality of the included studies was assessed according to the QUIPS instrument. Results The analysis included 17 studies comprising 3157 patients. Subgroup analyses were performed for cholangiocarcinoma (CCC), colorectal cancer (CRC) liver metastases, and hepatocellular carcinoma (HCC). LSMM as identified on CT was present in 1260 patients (39.9%). Analysis of the overall sample showed that LSMM was associated with higher post-operative complications grade Clavien Dindo ≥ 3 (OR 1.56, 95% CI 1.25–1.95, p < 0.001). In the subgroup analysis, LSMM was associated with post-operative complications in CRC metastases (OR 1.60, 95% CI 1.11–2.32, p = 0.01). In HCC and CCC sub-analyses, LSMM was not associated with post-operative complications in simple regression analysis. Conclusion LSMM is associated with major post-operative complications in patients undergoing surgery for hepatic metastases and it does not influence major post-operative complications in patients with HCC and CCC.

Impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer: a systematic review and meta-analysis

“…The results revealed a robust association between sarcopenia and/or SO and patient survival. A strong relationship between sarcopenia and adverse clinical outcomes in cancer patients has been reported in prior studies, including depression ( 83 ), risk of fall ( 84 ), higher risk of complications ( 85 ), and cancer recurrence and mortality ( 9 , 13 , 15 , 86 ). In 2022, a meta-analysis comprising 280 publications involving 81,814 patients with solid tumors demonstrated that sarcopenia is a prevalent condition in oncological patients with a prevalence of 35.3%; moreover, it is particularly higher in patients with specific cancer types such as esophageal cancer, urothelial cancer, cholangiocarcinoma, prostate cancer, and thyroid cancer ( 87 ).…”

Impact of sarcopenia on clinical outcomes for patients with resected hepatocellular carcinoma: a retrospective comparison of Eastern and Western cohorts

“… 38 and a meta-analysis by Thorman et al . 39 . The latter study described the effect of sarcopenia on severe complications (i.e.…”

Value of sarcopenia in the resection of colorectal liver metastases—a systematic review and meta-analysis

“…To the best of our knowledge, this is the first meta-analysis that deals with the influence of sarcopenia on the outcome of patients who undergo liver resection for colorectal liver metastases (CRLM) alone. CRLM patients have been incorporated into previous meta-analyses ( 36 , 37 ). However, due to the unique nature of CRLM and its rising incidence, preoperative assessment is more and more valued in this patient cohort ( 38 ).…”